secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-01-18T23:59:59+00:00
Accession:  0001193125-23-010273
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics prices upsized public offering of 9.6M shares at $13.00, expected gross proceeds of $125M
--------------------------------------------------------------------------------

- Offered 9,615,384 shares at $13.00 per share; gross proceeds of $125 million.
- Underwriters granted 30-day option to purchase up to an additional 1,442,307 shares.
- Net proceeds estimated at $117.3M ($134.9M if option fully exercised).
- Goldman Sachs, SVB Securities, Piper Sandler acting as joint book-running managers.
- Offering expected to close on January 20, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523010273/0001193125-23-010273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523010273/d451832d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-010273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer